The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer.

MLA

Liu, Chun, et al. “The Role of Plasma Exosomal Lnc-SNAPC5-3:4 in Monitoring the Efficacy of Anlotinib in the Treatment of Advanced Non-Small Cell Lung Cancer.” Journal of Cancer Research and Clinical Oncology, vol. 148, no. 10, Oct. 2022, pp. 2867–79. EBSCOhost, https://doi.org/10.1007/s00432-022-04071-5.

APA

Liu, C., Hu, C., Chen, T., Jiang, Y., Zhang, X., Liu, H., Wang, Y., Li, Z., Hui, K., & Jiang, X. (2022). The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 148(10), 2867–2879. https://doi.org/10.1007/s00432-022-04071-5

Chicago

Liu, Chun, Chenxi Hu, Ting Chen, Yanting Jiang, Xin Zhang, Hongyu Liu, Yuan Wang, Zhi Li, Kaiyuan Hui, and Xiaodong Jiang. 2022. “The Role of Plasma Exosomal Lnc-SNAPC5-3:4 in Monitoring the Efficacy of Anlotinib in the Treatment of Advanced Non-Small Cell Lung Cancer.” Journal of Cancer Research and Clinical Oncology 148 (10): 2867–79. doi:10.1007/s00432-022-04071-5.